CorMedix (CRMD) Gains from Investment Securities (2015 - 2025)

CorMedix (CRMD) posted Gains from Investment Securities of -$2.3 million for Q4 2025, down 225381.57% sequentially from $1009.0 in Q1 2019.

CorMedix (CRMD) Gains from Investment Securities (2015 - 2025) Analysis & Trends

CorMedix has reported Gains from Investment Securities for 5 years, with the latest figure at -$2.3 million in Q4 2025.

Quarterly Gains from Investment Securities changed N/A year-over-year to -$2.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$2.3 million (changed N/A YoY) and the FY2025 annual result came in at -$5.4 million, changed N/A from the prior year.
Gains from Investment Securities eased to -$2.3 million in Q4 2025 per CRMD's latest filing, from $1009.0 in the prior quarter.
Over five years, Gains from Investment Securities peaked at -$2.3 million in Q4 2025 and troughed at -$2.3 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	CorMedix	645.20 Mn	388.51 Mn	77.13 Mn

Download Data